A Phase I clinical trial evaluating XmAb-18087 for the treatment of neuroendocrine tumors and GIST.
Phase of Trial: Phase I
Latest Information Update: 11 Jan 2018
At a glance
- Drugs XmAb-18087 (Primary)
- Indications Gastrointestinal stromal tumours; Neuroendocrine tumours
- Focus Adverse reactions
- 11 Jan 2018 New trial record
- 05 Jan 2018 According to a Xencor media release, the company is planning to initiate this trial in first quarter of 2018.